Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer

Oumi Nakajima, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara, Tomohisa Horibe, Masayuki Kohno, Koji Kawakami

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.

Original languageEnglish
Pages (from-to)1039-1043
Number of pages5
JournalOncology Reports
Volume22
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Head and Neck Neoplasms
Heterografts
Neoplasms
Immunochemistry
Injections
Telomerase
Natural Killer Cells
Appointments and Schedules
Macrophages
Cell Line
Therapeutics
Growth
Carcinoma, squamous cell of head and neck

Keywords

  • Adenovirus
  • OBP-301
  • Squamous cell carcinoma of the head and neck
  • Telomelysin
  • Telomerase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakajima, O., Ichimaru, D., Urata, Y., Fujiwara, T., Horibe, T., Kohno, M., & Kawakami, K. (2009). Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. Oncology Reports, 22(5), 1039-1043. https://doi.org/10.3892/or_00000533

Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. / Nakajima, Oumi; Ichimaru, Daiju; Urata, Yasuo; Fujiwara, Toshiyoshi; Horibe, Tomohisa; Kohno, Masayuki; Kawakami, Koji.

In: Oncology Reports, Vol. 22, No. 5, 2009, p. 1039-1043.

Research output: Contribution to journalArticle

Nakajima, O, Ichimaru, D, Urata, Y, Fujiwara, T, Horibe, T, Kohno, M & Kawakami, K 2009, 'Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer', Oncology Reports, vol. 22, no. 5, pp. 1039-1043. https://doi.org/10.3892/or_00000533
Nakajima, Oumi ; Ichimaru, Daiju ; Urata, Yasuo ; Fujiwara, Toshiyoshi ; Horibe, Tomohisa ; Kohno, Masayuki ; Kawakami, Koji. / Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. In: Oncology Reports. 2009 ; Vol. 22, No. 5. pp. 1039-1043.
@article{6a8ea77f04824f6381044f79c4097fcf,
title = "Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer",
abstract = "We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.",
keywords = "Adenovirus, OBP-301, Squamous cell carcinoma of the head and neck, Telomelysin, Telomerase",
author = "Oumi Nakajima and Daiju Ichimaru and Yasuo Urata and Toshiyoshi Fujiwara and Tomohisa Horibe and Masayuki Kohno and Koji Kawakami",
year = "2009",
doi = "10.3892/or_00000533",
language = "English",
volume = "22",
pages = "1039--1043",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer

AU - Nakajima, Oumi

AU - Ichimaru, Daiju

AU - Urata, Yasuo

AU - Fujiwara, Toshiyoshi

AU - Horibe, Tomohisa

AU - Kohno, Masayuki

AU - Kawakami, Koji

PY - 2009

Y1 - 2009

N2 - We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.

AB - We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.

KW - Adenovirus

KW - OBP-301

KW - Squamous cell carcinoma of the head and neck

KW - Telomelysin

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=70449448159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449448159&partnerID=8YFLogxK

U2 - 10.3892/or_00000533

DO - 10.3892/or_00000533

M3 - Article

C2 - 19787218

AN - SCOPUS:70449448159

VL - 22

SP - 1039

EP - 1043

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -